Cormedix Q4 GAAP EPS $(0.26) Misses $(0.20) Estimate; Cash And Short-Term Investments Of $76M
Portfolio Pulse from Benzinga Newsdesk
Cormedix reported a Q4 GAAP EPS of $(0.26), missing the $(0.20) estimate by 30%, with a year-over-year decrease in earnings. They have $76M in cash and short-term investments.
March 12, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cormedix reported a larger than expected quarterly loss and a decrease in earnings compared to last year, with $76M in cash and short-term investments.
The reported earnings miss and year-over-year decrease in earnings are likely to negatively impact investor sentiment and the stock price in the short term. The company's financial position, indicated by its cash and short-term investments, may provide some cushion, but the immediate reaction to earnings misses is typically negative.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100